1029 related articles for article (PubMed ID: 27583876)
41. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC).
Zeng T; Qin Q; Bian Z; Li J
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4194-4201. PubMed ID: 31713435
[No Abstract] [Full Text] [Related]
42. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
[TBL] [Abstract][Full Text] [Related]
43. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
[TBL] [Abstract][Full Text] [Related]
44. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN; Lu WQ; Yang BW; Zhang LY; Jin B; Wang S; Che XF; Li C; Liu YP; Qu XJ
Front Immunol; 2021; 12():666909. PubMed ID: 34149702
[TBL] [Abstract][Full Text] [Related]
45. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
Tartarone A; Roviello G; Lerose R; Roudi R; Aieta M; Zoppoli P
Future Oncol; 2019 Jul; 15(20):2423-2433. PubMed ID: 31237152
[No Abstract] [Full Text] [Related]
46. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
[TBL] [Abstract][Full Text] [Related]
47. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
[TBL] [Abstract][Full Text] [Related]
48. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Antonia SJ; Borghaei H; Ramalingam SS; Horn L; De Castro Carpeño J; Pluzanski A; Burgio MA; Garassino M; Chow LQM; Gettinger S; Crinò L; Planchard D; Butts C; Drilon A; Wojcik-Tomaszewska J; Otterson GA; Agrawal S; Li A; Penrod JR; Brahmer J
Lancet Oncol; 2019 Oct; 20(10):1395-1408. PubMed ID: 31422028
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
[TBL] [Abstract][Full Text] [Related]
50. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
51. Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
Pilotto S; Carbognin L; Rossi A; Tortora G; Bria E
Semin Oncol; 2018 Jun; 45(3):176-180. PubMed ID: 30262399
[TBL] [Abstract][Full Text] [Related]
52. Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhuansun Y; Huang F; Du Y; Lin L; Chen R; Li J
J Thorac Dis; 2017 Mar; 9(3):655-665. PubMed ID: 28449473
[TBL] [Abstract][Full Text] [Related]
53. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
Xu X; Huang Z; Zheng L; Fan Y
Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
[TBL] [Abstract][Full Text] [Related]
54. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
[No Abstract] [Full Text] [Related]
55. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
56. PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
Di Federico A; De Giglio A; Nuvola G; Deiana C; Conci N; Gelsomino F; Ardizzoni A
Future Oncol; 2021 Nov; 17(32):4415-4424. PubMed ID: 34402681
[No Abstract] [Full Text] [Related]
57. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Jiang J; Huang L; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Acta Oncol; 2011 May; 50(4):582-8. PubMed ID: 21190510
[TBL] [Abstract][Full Text] [Related]
58. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
60. The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients.
Chen RL; Zhou JX; Cao Y; Li SH; Li YH; Jiang M; Lu DY; Li P; Lin LZ
Immunotherapy; 2019 Dec; 11(17):1481-1490. PubMed ID: 31713453
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
